Mwyngil Therapeutics launches obesity program that avoids GLP-1 pathway
Mwyngil Therapeutics, a newly formed biotech startup, is pursuing obesity treatments that do not target the GLP-1 receptor, a pathway that has dominated recent weight-loss drug development.
CEO Luba Greenwood said the company wants to move beyond "me-too" GLP-1 candidates and explore alternative mechanisms for weight loss.
The approach reflects a broader interest in diversifying obesity therapeutics, even as GLP-1 drugs dominate public attention and market activity.
Mwyngil's strategy is still early-stage, and the company has not disclosed specific candidates or timelines for clinical testing.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect”
read at STAT ↗
comments(0)
5-min edit window · permanent after that